Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Deferred tax liabilities by Year
Deferred tax liabilities — Operating lease ROU assets ($M) ($M)
Vertex Pharmaceuticals Deferred tax liabilities: $313M in FY2025, up 15.0% from a year earlier.
Latest, FY2025
313
Period ended Dec 31, 2025
Change on a year earlier
+15.0%
272 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax liabilities — Operating lease ROU assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 313 | +15.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 272 | +389.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 55.6 | -11.9% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 63.1 | -2.6% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 64.8 | +2.4% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 63.3 | +383.2% | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 13.1 | – | Form 10-K (filed 2021-02-11) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Deferred tax liabilities ($M), annual FY2019–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/dtl-lease
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.